Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase 1/2a clinical trial; and CLS-301, an integrin inhibitor suspension for the treatment of diabetic macular edema and macular degeneration. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CEO

Dr. George M. Lasezkay J.D., Pharm.D., Pharma.D.

Employees

Country

United States

ISIN

US1850632035

Listings

0 Comments

Share your thoughts

FAQ

What is Clearside Biomedical stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Clearside Biomedical stocks are traded under the ticker CLM0.MU.

Is Clearside Biomedical stock price growing?▼

CLM0.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Clearside Biomedical has showed a -60% decrease.

How many employees does Clearside Biomedical have?▼

As of April 30, 2026, the company has 32 employees.

In which sector is Clearside Biomedical located?▼

Clearside Biomedical operates in the Health & Wellness sector.

When did Clearside Biomedical complete a stock split?▼

Clearside Biomedical has not had any recent stock splits.

Where is Clearside Biomedical headquartered?▼

Clearside Biomedical is headquartered in Alpharetta, United States.